Jamey Marth, Ph.D.
Jamey Marth's Research Focus
Research in the Marth laboratory is centered upon protein glycosylation in the cell biology of disease. The laboratory develops and applies biomedical nanotechnologies in discovering how protein glycosylation participates in the metabolic origins and mechanisms of syndromes including diabetes, autoimmunity, inflammation, cancer, and sepsis. The incorporation of various nanotechnologies into biomedical research is becoming important in the investigation of diseases caused by metabolic and environmental factors that reflect template-independent non-genetic mechanisms.
Previous progress by this laboratory included the development of Cre-loxP conditional mutagenesis, a technique that enables cell type-selective and temporally regulated remodeling of the genome in multicellular organisms including mammals. The laboratory applies this technology in the context of transgenesis and gene-targeting to investigate the functions of protein glycosylation and the resulting glycan linkages produced in cells and tissues of living mammals. Glycans are one of the four main families of organic molecules of cells with nucleic acids, proteins, and lipids. Like protein phosphorylation, glycosylation is a metabolic process that alters protein structure and function. This laboratory has found that alterations in protein glycosylation caused by environmental and metabolic stimuli substantially contribute to the origin and severity of diseases and syndromes including obesity-associated diabetes, sepsis, and chronic inflammatory states that develop into more severe disorders including tissue degeneration and autoimmunity.
Cancer is another disease wherein significant metabolic signposts include altered glycosylation of proteins. Such highly expressed cell surface tumor antigens that combine glycan and protein sequences in unique combinations may enable more selective drug delivery at high efficiency to further improve upon cancer treatment by nanomedicine.
The laboratory includes interdisciplinary research in collaborations with bioengineers and clinicians to develop improved diagnostic and therapeutic strategies that can detect and intervene in the early cellular dysfunction of disease. These discoveries provide a rationale for therapeutic development efforts that leverages our understanding of metabolic components and environmental factors to more effectively intervene in the onset and progression of disease.
Jamey Marth's Bio
Jamey Marth is Professor and Director of the University of California Santa Barbara Center for Nanomedicine, and of the Sanford-Burnham Medical Research Institute. He is also a Professor in the UCSB Department of Molecular, Cellular and Developmental Biology, and in the UCSB Biomolecular Science and Engineering program. Dr. Marth is the inaugural recipient of the UCSB Carbon Endowed Chair of Biochemistry and Molecular Biology and a recipient of the UCSB Mellichamp Endowed Chair of Systems Biology. Dr. Marth received a Ph.D. degree in Pharmacology from the University of Washington where he trained in the laboratories of Roger M. Perlmutter, current Executive Vice-President of Merck, and the late Edwin G. Krebs, a 1992 Nobel Prize laureate. Dr. Marth was recruited to University of California San Diego in 1995 by George Palade – a 1974 Nobel Prize laureate, where he was appointed as an Investigator of the Howard Hughes Medical Institute and Professor in the Department of Cellular and Molecular Medicine, prior to his current positions.
1987: Ph.D., University of Washington, Pharmacology
1984: B.S., University of Oregon, Genetics and Chemistry
Carbon Chair of Biochemistry and Molecular Biology, UCSB
Mellichamp Chair of Systems Biology, UCSB
Honors and Recognition
2009-Present: John Carbon Chair in Biochemistry and Molecular Biology
2009-Present: Duncan and Suzanne Mellichamp Chair in Systems Biology
1995-2009: Investigator, Howard Hughes Medical Institute
1999-2009: University of California San Diego, Professor
1991-1995: Faculty Scholarship, The Medical Research Council of Canada
Orban PC, Chui D, Marth JD
Proc Natl Acad Sci U S A 1992 Aug 1 ;89(15):6861-5
Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K
Science 1994 Jul 1 ;265(5168):103-6
Glycoconj J 1994 Feb ;11(1):3-8
Dual actions of group B <i>Streptococcus</i> capsular sialic acid provide resistance to platelet-mediated antimicrobial killing.
Uchiyama S, Sun J, Fukahori K, Ando N, Wu M, Schwarz F, Siddiqui SS, Varki A, Marth JD, Nizet V
Proc Natl Acad Sci U S A 2019 Apr 9 ;116(15):7465-7470
Pimienta G, Heithoff DM, Rosa-Campos A, Tran M, Esko JD, Mahan MJ, Marth JD, Smith JW
Proteomics 2019 Mar ;19(5):e1800389
Barnes L, Heithoff DM, Mahan SP, Fox GN, Zambrano A, Choe J, Fitzgibbons LN, Marth JD, Fried JC, Soh HT, Mahan MJ
EBioMedicine 2018 Oct ;36:73-82
Yang WH, Heithoff DM, Aziz PV, Sperandio M, Nizet V, Mahan MJ, Marth JD
Science 2017 Dec 22 ;358(6370)
Ersoy SC, Heithoff DM, Barnes L 5th, Tripp GK, House JK, Marth JD, Smith JW, Mahan MJ
EBioMedicine 2017 Jun ;20:173-181
Varki A, Cummings RD, Aebi M, Packer NH, Seeberger PH, Esko JD, Stanley P, Hart G, Darvill A, Kinoshita T, Prestegard JJ, Schnaar RL, Freeze HH, Marth JD, Bertozzi CR, Etzler ME, Frank M, Vliegenthart JF, Lütteke T, Perez S, Bolton E, Rudd P, Paulson J, Kanehisa M, Toukach P, Aoki-Kinoshita KF, Dell A, Narimatsu H, York W, Taniguchi N, Kornfeld S
Glycobiology 2015 Dec ;25(12):1323-4